newsfilter
← Latest News
GlobeNewswire·

Cartesian Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Company expects to commence Phase 3 trial of Descartes-08 in patients with myasthenia gravis in 1H2025 following recent meeting with U.S. Food and Drug Administration Presentation of updated efficacy and safety